Menopause hormone therapy significantly alters pathophysiological biomarkers of Alzheimer's disease

This increasing body of literature indicates that menopause hormonal replacement therapy (MHT) may substantially mitigate the risk of developing late‐life cognitive decline due to progressive Alzheimer's disease (AD) pathophysiology. For the first time, we investigated the question whether MHT impacts AD biomarker‐informed pathophysiological dynamics in de‐novo diagnosed menopausal women.

[1]  Jacob Cohen.  Statistical Power Analysis for the Behavioral Sciences , 1969, The SAGE Encyclopedia of Research Design.

[2]  H. Kamel,et al.  Association of Reproductive History With Brain MRI Biomarkers of Dementia Risk in Midlife , 2021, Neurology.

[3]  K. Blennow,et al.  Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease , 2021, JAMA neurology.

[4]  J. Hort,et al.  Proportion of Women and Reporting of Outcomes by Sex in Clinical Trials for Alzheimer Disease: A Systematic Review and Meta-analysis. , 2021, JAMA network open.

[5]  C. Masters,et al.  The Amyloid-β Pathway in Alzheimer’s Disease , 2021, Molecular Psychiatry.

[6]  A. Ciapponi,et al.  Mini-Mental State Examination (MMSE) for the early detection of dementia in people with mild cognitive impairment (MCI). , 2021, The Cochrane database of systematic reviews.

[7]  Wei Zhao,et al.  Estrogen Deficiency Induces Mitochondrial Damage Prior to Emergence of Cognitive Deficits in a Postmenopausal Mouse Model , 2021, Frontiers in Aging Neuroscience.

[8]  C. Jack,et al.  Developing the ATX(N) classification for use across the Alzheimer disease continuum , 2021, Nature Reviews Neurology.

[9]  P. Svenningsson,et al.  A multicentre validation study of the diagnostic value of plasma neurofilament light , 2021, Nature Communications.

[10]  Yanghua Tian,et al.  Sex Difference in Network Topology and Education Correlated With Sex Difference in Cognition During the Disease Process of Alzheimer , 2021, Frontiers in Aging Neuroscience.

[11]  C. Cervellati,et al.  BACE1: from biomarker to Alzheimer’s disease therapeutical target , 2021, Aging.

[12]  Corinne E. Fischer,et al.  Diagnostic Precision in the Detection of Mild Cognitive Impairment: A Comparison of Two Approaches. , 2021, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[13]  S. Gauthier,et al.  Interactive rather than independent effect of APOE and sex potentiates tau deposition in women , 2021, Brain communications.

[14]  K. Blennow,et al.  Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology , 2021, Acta Neuropathologica.

[15]  K. Blennow,et al.  Plasma β‐secretase1 concentrations correlate with basal forebrain atrophy and neurodegeneration in cognitively healthy individuals at risk for AD , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[16]  M. D. de Leon,et al.  Menopause impacts human brain structure, connectivity, energy metabolism, and amyloid-beta deposition , 2021, Scientific Reports.

[17]  Garam Lee,et al.  Alzheimer's disease drug development pipeline: 2021 , 2021, Alzheimer's & dementia.

[18]  P. Scheltens,et al.  Highly specific and ultrasensitive plasma test detects Abeta(1–42) and Abeta(1–40) in Alzheimer’s disease , 2020, Scientific Reports.

[19]  B. de Strooper,et al.  The β-Secretase BACE1 in Alzheimer’s Disease , 2020, Biological Psychiatry.

[20]  F. Ramus,et al.  Neuroanatomical norms in the UK Biobank: The impact of allometric scaling, sex, and age , 2020, bioRxiv.

[21]  A. Fornito,et al.  Interactions between Age, Sex, Menopause and Brain Structure at Midlife: A UK Biobank Study. , 2020, The Journal of clinical endocrinology and metabolism.

[22]  K. Blennow,et al.  Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected , 2020, EMBO molecular medicine.

[23]  M. Sabbagh,et al.  Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval , 2020, Alzheimer's Research & Therapy.

[24]  Ling Chen,et al.  Estradiol Replacement at the Critical Period Protects Hippocampal Neural Stem Cells to Improve Cognition in APP/PS1 Mice , 2020, Frontiers in Aging Neuroscience.

[25]  M. D. de Leon,et al.  Sex-driven modifiers of Alzheimer risk , 2020, Neurology.

[26]  N. Toschi,et al.  A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease , 2020, Frontiers in Immunology.

[27]  R. Brinton,et al.  Transitions in metabolic and immune systems from pre-menopause to post-menopause: implications for age-associated neurodegenerative diseases , 2020, F1000Research.

[28]  Samuel E. Zimmerman,et al.  Estrogen activates Alzheimer's disease genes , 2019, Alzheimer's & dementia.

[29]  Keith A. Johnson,et al.  Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults , 2019, JAMA neurology.

[30]  M. Ferretti,et al.  Account for sex in brain research for precision medicine , 2019, Nature.

[31]  M. D. de Leon,et al.  Increased Alzheimer's risk during the menopause transition: A 3-year longitudinal brain imaging study , 2018, PloS one.

[32]  R. Brinton,et al.  Inflammation: Bridging Age, Menopause and APOEε4 Genotype to Alzheimer’s Disease , 2018, Front. Aging Neurosci..

[33]  Simone Lista,et al.  Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic , 2018, Nature Reviews Neurology.

[34]  for the Alzheimer’s Disease Neuroimaging Initiative,et al.  Sex differences in Alzheimer disease — the gateway to precision medicine , 2018, Nature Reviews Neurology.

[35]  O. Sporns,et al.  Sex differences in functional and molecular neuroimaging biomarkers of Alzheimer's disease in cognitively normal older adults with subjective memory complaints , 2018, Alzheimer's & Dementia.

[36]  K. Kantarci,et al.  Understanding the impact of sex and gender in Alzheimer's disease: A call to action , 2018, Alzheimer's & Dementia.

[37]  G. Bu,et al.  Apolipoprotein E, Receptors, and Modulation of Alzheimer’s Disease , 2018, Biological Psychiatry.

[38]  T. Simoncini,et al.  Symptoms of menopause — global prevalence, physiology and implications , 2018, Nature Reviews Endocrinology.

[39]  A. Ripka.  Faculty of 1000 evaluation for Sex differences in Alzheimer risk: Brain imaging of endocrine vs chronologic aging. , 2018 .

[40]  D. Rujescu,et al.  Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer’s Disease Dementia in Individuals With Mild Cognitive Impairment , 2017, Biological Psychiatry.

[41]  M. D. de Leon,et al.  Perimenopause and emergence of an Alzheimer’s bioenergetic phenotype in brain and periphery , 2017, PloS one.

[42]  Tanya P. Garcia,et al.  Statistical Approaches to Longitudinal Data Analysis in Neurodegenerative Diseases: Huntington’s Disease as a Model , 2017, Current Neurology and Neuroscience Reports.

[43]  S. Correia,et al.  Middle-Aged Diabetic Females and Males Present Distinct Susceptibility to Alzheimer Disease-like Pathology , 2016, Molecular Neurobiology.

[44]  H. Depypere,et al.  Alzheimer's disease, apolipoprotein E and hormone replacement therapy. , 2016, Maturitas.

[45]  S. Klein,et al.  Sex differences in immune responses , 2016, Nature Reviews Immunology.

[46]  N. Panay,et al.  2016 IMS Recommendations on women’s midlife health and menopause hormone therapy , 2016, Climacteric : the journal of the International Menopause Society.

[47]  E. Cadenas,et al.  Perimenopause as a neurological transition state , 2015, Nature Reviews Endocrinology.

[48]  L. Jäncke,et al.  Brain size, sex, and the aging brain , 2015, Human brain mapping.

[49]  J. Manson,et al.  Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women's health initiative randomized trials , 2014 .

[50]  E. Reiman,et al.  Polymorphism of brain derived neurotrophic factor influences β amyloid load in cognitively intact apolipoprotein E ε4 carriers , 2013, NeuroImage: Clinical.

[51]  C. Farquhar,et al.  Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. , 2009, The Cochrane database of systematic reviews.

[52]  Giovanni Coppola,et al.  Gender Modulates the APOE ε4 Effect in Healthy Older Adults: Convergent Evidence from Functional Brain Connectivity and Spinal Fluid Tau Levels , 2012, The Journal of Neuroscience.

[53]  V. Miller.  Family matters: sexual dimorphism in cardiovascular disease , 2012, The Lancet.

[54]  J. Morrison,et al.  Interactive effects of age and estrogen on cortical neurons: implications for cognitive aging , 2011, Neuroscience.

[55]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[56]  H. Depypere,et al.  A 60-month non-comparative study on bleeding profiles with the levonorgestrel intrauterine system from the late transition period to estrogen supplemented menopause. , 2010, European journal of obstetrics, gynecology, and reproductive biology.

[57]  C. Farquhar,et al.  Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. , 2009, The Cochrane database of systematic reviews.

[58]  P. Maki.  The timing of estrogen therapy after ovariectomy—implications for neurocognitive function , 2008, Nature Clinical Practice Endocrinology &Metabolism.

[59]  C. Gallagher.  Extending the Linear Model With R: Generalized Linear, Mixed Effects and Nonparametric Regression Models , 2007 .

[60]  J. Morrison,et al.  Interactive effects of age and estrogen on cognition and pyramidal neurons in monkey prefrontal cortex , 2007, Proceedings of the National Academy of Sciences.

[61]  F. Clavel-Chapelon,et al.  Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study , 2007, Breast Cancer Research and Treatment.

[62]  H. Soininen,et al.  CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. , 2006, Brain : a journal of neurology.

[63]  Alan C. Evans,et al.  Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. , 2005, Archives of neurology.

[64]  D. Murphy,et al.  The Women's Health Initiative Memory Study: findings and implications for treatment , 2005, The Lancet Neurology.

[65]  L. Thal,et al.  Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study , 2004, JAMA.

[66]  Ján,et al.  Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. , 1995, JAMA.

[67]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.